Our Vision Portfolio About Contact

Strategic development design of
Clinical & Translational Studies

We become embedded in your team as your Clinical & Translational Scientists — designing the architecture of your studies from Hypothesis to Interpretation.

Five stages of study design

Across every program type, the design of a study follows the same arc — from the foundation of the hypothesis through to the interpretation of results.

01
Stage One
Scientific Foundation

We examine and document the scientific basis of the program — building the structured argument on which every downstream design decision depends.

  • Mechanistic rationale
  • Signal and biomarker landscape
  • Methodological validity
  • Evidence synthesis
  • Assumption map
02
Stage Two
Study Design

We design the scientific architecture of the study — the question, the endpoints, and the definition of what a meaningful result looks like, grounded in the biology.

  • Study rationale
  • Endpoint selection
  • Success criteria
  • Study type design
  • Confounder strategy
03
Stage Three
Execution Specification

We specify every operational element of the study — who is enrolled, what is measured, when, and how — each decision traced back to a scientific rationale.

  • Population definition
  • Sample collection design
  • Assay specifications
  • Specimen management
  • Site capability criteria
04
Stage Four
Analysis Planning

We define the analytical framework before data collection begins — locking the questions, the methods, and the decision rules the analysis will follow.

  • Analytical question specification
  • Analytical method design
  • Subgroup rationale
  • Data quality criteria
  • Missing data strategy
05
Stage Five
Data Interpretation

We evaluate the data against the mechanistic predictions that opened the study — producing a scientific interpretation and the program recommendations that follow from it.

  • Results evaluation
  • Endpoint assessment
  • Subgroup analysis
  • Unexpected findings investigation
  • Program recommendations
  • Scientific narrative

What makes the data interpretable

The four methodological conditions.

01
Pre-specification

The analytical plan is specified prior to the collection of the first sample. A plan written after data exists is a hypothesis, not a finding.

Analysis planned before enrolment
02
Mechanism-driven endpoints

Endpoints are determined with mechanistic and biological insights and not based on whether they are convenient or previously accepted.

Biology drives measurement selection
03
Explicit assumptions

Every assumption the study requires is documented before the protocol is written. Hidden assumptions cannot be tested or defended.

Assumptions documented, not buried
04
Interpretability over significance

A result is only valuable if it is actionable when positive and decisive when negative. Statistical significance is not a substitute for design rigour.

Design determines the value of the result

The studies we design

Our practice spans the full research arc — from the earliest mechanistic discovery studies through to clinical trials.

01
Program Type
Discovery Research
Target identificationGenomics, proteomics, systems biology-driven hypothesis design
Target validationKnockouts, in vitro efficacy, functional assay design
In silico screeningComputational model design and validation frameworks
Biomarker discoverySignal prioritization and early evidence synthesis
02
Program Type
Pre-clinical Studies
In vivo pharmacologyEfficacy and mechanistic model design with pre-specified endpoints
PK/PD studiesPharmacokinetic and pharmacodynamic study architecture
Safety and toxicologyNon-GLP and GLP study scientific framework design
IND-enabling packageScientific documentation architecture for regulatory readiness
03
Program Type
Co-clinical & Translational
Biomarker validationScientific design for companion biomarker qualification programs
Translational bridgingStudy architecture connecting mechanistic evidence to clinical hypothesis
Patient stratificationBiological framework design for target population definition
First-in-human biomarkerTranslational scientific design for Phase I entry
04
Program Type
Clinical Development
Phase I / II / IIIBiomarker-driven clinical study architecture with pre-specified scientific rationale
Basket & umbrella trialsScientific frameworks for multi-cohort precision oncology programs
Investigator-initiated trialsScientific architecture for physician-led studies
Adaptive study designPre-specified decision rules and scientific evaluation frameworks